Personalized Medicine in Autism Spectrum Disorder: Integrating Epigenomics, Microbiome Research and Early Diagnostics
International Journal of Developmental Neuroscience · 2026
DOI: 10.1002/jdn.70128 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Developmental Neuroscience, 2026. Verfasst von Amr Ali Mohamed Abdelgawwad El Sehrawy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Diabetes, Endocrinology and Metabolism, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Epigenomics, Precision Medicine, Gastrointestinal Microbiome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 108 Literaturangaben.
Abstract (Originalsprache)
Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by persistent difficulties in social communication together with restricted, repetitive patterns of behaviour and sensory‐processing differences. Growing evidence suggests that ASD is shaped by complex interactions among genetic susceptibility, epigenetic regulation, immune signalling, maternal and early‐life exposures and gut microbiome‐related pathways. However, many of these associations remain biologically plausible rather than definitively causal, particularly when findings from experimental models are considered alongside human clinical data. This narrative review examines recent advances across these interconnected domains, with particular emphasis on maternal immune activation, prenatal nutrition, gut microbial imbalance, epigenetic and molecular mechanisms, emerging therapeutic directions and developing biomarker platforms. We also discuss current diagnostic limitations and evaluate the potential of salivary microRNAs, perinatal metabolic and epigenetic markers, oxidative stress‐related measures and microbiome‐based profiles as early and biologically informative indicators of ASD risk. Special attention is given to the need for biologically informed stratification, although current subgrouping frameworks remain preliminary and not yet sufficiently validated for routine clinical use. Likewise, candidate biomarkers remain investigational and require stronger evidence for reproducibility, external validation, longitudinal performance and clinically meaningful sensitivity and specificity before they can be considered for screening or precision‐guided care. Emerging therapeutic strategies targeting immune, epigenetic and microbiome‐related pathways are also reviewed, but most remain preclinical or early‐stage and face substantial translational barriers. The convergence of epigenomics, microbiome research and early diagnostic science may help advance a more personalized medicine framework for ASD, provided that future studies improve cross‐cohort reproducibility, clarify brain relevance of peripheral signals and develop practical multiomics models that can support clinically meaningful integration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Diabetes, Endocrinology and Metabolism, Mansoura University, Mansoura, Egypt.
- Pharmacy College, University of Al Maarif, Al Anbar, Iraq.
- Department of Basic Medical Sciences, Termez University of Economics and Service, Termez, Uzbekistan.
- Special Education Department, College of Education, King Khalid University, Abha, Saudi Arabia.
- Diabetes & Chronic Diseases Unit Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.
- Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
ORCID-Profile: Amr Ali Mohamed Abdelgawwad El Sehrawy, Ulugbek Axmedov, Mohamad Ahmad Saleem Khasawneh, Mansuor A Alanazi, Aseel Smerat, Tina Saeed Basunduwah
Zitieren
APA
El Sehrawy, A. A. M. A., Aljumaili, O. I., Axmedov, U., Khasawneh, M. A. S., Alanazi, M. A., Smerat, A., & Basunduwah, T. S. (2026). Personalized Medicine in Autism Spectrum Disorder: Integrating Epigenomics, Microbiome Research and Early Diagnostics. International Journal of Developmental Neuroscience. https://doi.org/10.1002/jdn.70128
Vancouver
El Sehrawy AAMA, Aljumaili OI, Axmedov U, Khasawneh MAS, Alanazi MA, Smerat A, et al. Personalized Medicine in Autism Spectrum Disorder: Integrating Epigenomics, Microbiome Research and Early Diagnostics. International Journal of Developmental Neuroscience. 2026. doi:10.1002/jdn.70128
BibTeX
@article{ElSehrawy2026,
author = {El Sehrawy, Amr Ali Mohamed Abdelgawwad and Aljumaili, Omar I and Axmedov, Ulugbek and Khasawneh, Mohamad Ahmad Saleem and Alanazi, Mansuor A and Smerat, Aseel and Basunduwah, Tina Saeed},
title = {Personalized Medicine in Autism Spectrum Disorder: Integrating Epigenomics, Microbiome Research and Early Diagnostics},
journal = {International Journal of Developmental Neuroscience},
year = {2026},
doi = {10.1002/jdn.70128}
}
EUVIMED